VIDAZA® Treatment for MDSa

About VIDAZA®

Give your patients the standard of care for Int-2 and High-risk MDSa.1,2

VIDAZA® is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation with:

  • intermediate-2 and high-risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS)
  • chronic myelomonocytic leukaemia (CMML) with 10-29% marrow blasts without myeloproliferative disorder
  • acute myeloid leukaemia (AML) with 20-30% blasts and multi-lineage dysplasia, according to World Health Organisation (WHO) classification1

VIDAZA® is the first drug treatment to significantly prolong overall survival and alter the natural history of the disease.3

  • VIDAZA® significantly improves survival by doubling the 2-year survival rate compared to CCR (p<0.0001)
  • VIDAZA® leads to a reduced need for red blood cell (RBC) transfusions
  • Patients should be treated as long as they continue to benefit or until disease progressions
  • VIDAZA® has a well characterised side effect profile that in most cases can be managed to allow continuous treatment1,3

Intermediate-2 and high-risk myelodysplastic syndromes are fatal haematological malignancies.4

Myelodysplastic Syndromes Survival Rate

Median survival for:

  • Int-2 MDS patients: 1.2 years
  • High-risk MDS patients: 0.4 years

Progression from MDS to acute myeloid leukaemia (AML) is common4

MDS Progression to acute myeloid leukaemia (AML)

Median time to 25% AML progression:

  • Int-2 MDS patients: 1.1 years
  • High-risk MDS patients: 0.2 years

VIDAZA® – the first agent to significantly extend survival in higher-risk MDSa patients3

VIDAZA® doubles the 2-year survival rate from 26% to 51% (p<0.0001) compared with conventional care regimens (CCR)

VIDAZA® MDS survival rate compared with conventional care regimens (CCR)

VIDAZA® significantly increases median OS to 24.5 months vs. 15 months with CCR3

*IPPS; International Prognostic Scoring System

†Conventional care regimens (Best supportive care [BSC] only, included in each arm, n=105; Low dose Ara-C

[LDAC, 20mg/m2/d x 14d q28d], n=49; Intensive chemo [Ara-C, 100-200mg/m2/d by continuous IV infusion x 7d+3d IV daunorubicin 45-60mg/m2/d, idarubicin 9-12mg/m2/d, or mitoxantrone 8-12mg/m2/d], n=25)2

  1. VIDAZA® Summary of Product Characteristics, 2011.
  2. Fenaux. P. et al. Blood. 2007. 110: Abstract 817.
  3. Fenaux P. et al. Lancet Oncology 2009. 10:223-232.
  4. Greenberg P et al. Blood 1997. 89: 2079-88.
a. MDS-specific Indication

VIDAZA® is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation with:

  • intermediate-2 and high-risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS),
  • chronic myelomonocytic leukaemia (CMML) with 10-29% marrow blasts without myeloproliferative disorder
b. AML-specific Indication:

Treatment of adult AML patients who are not eligible for haematopoietic stem cell transplantation with 20-30% blasts and multi-lineage dysplasia, according to the WHO classification. WHO classifies RAEB-T patients with blasts ≥20% to <30% as AML patients.

Disclaimer

This is an international website for VIDAZA® and is intended for healthcare professionals outside the US. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.

The information on this website is based on the European Summary of Product Characteristics (SmPC). Please refer to your country-specific website, or contact a Celgene representative in your country for the latest information specific to your country.